🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

54 results for “extended-release” Clear

  1. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  2. SPD503 (extended-release Guanfacine hydrochloride)

    Takeda

    Generalized Anxiety Disorder (GAD)

    phase 2 small molecule completed

    1 trial

  3. Sialic Acid Extended Release (SA-ER)

    Ultragenyx UK Limited

    GNE Myopathy

    phase 2 small molecule completed

    1 trial

  4. VIVITROL (Naltrexone extended-release injectable suspension)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  5. extended-release buprenorphine (BXR)

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule on hold

    1 trial

  6. 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)

    Teva Pharma GmbH

    Drug Abuse

    phase 1 small molecule completed

    1 trial

  7. 90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).

    Teva Pharma GmbH

    Pain

    phase 1 small molecule completed

    1 trial

  8. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  9. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  10. Alprazolam Extended-Release 3 mg Tablets

    Teva Pharma GmbH

    Healthy

    phase 1 small molecule completed

    2 trials

  11. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial

  12. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Tamsulosin Hydrochloride Capsules USP 0.4 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Tamsulosin Hydrochloride extended-release capsules 0.4 mg, Product of Geolab Indústria Farmacêutica S/A, VP. 1B QD.08-B Modules 01 to 08, DAIA - Anápolis – GO, in healthy adult, human male subjects under fed condition.

    Lacuna Pharma Pty Ltd

    Benign prostatic hyperplasia (BPH)

    phase 1 other active

    1 trial

  13. DepoDur (extended-release epidural morphine)

    Pacira Ireland Limited

    Postoperative Pain

    phase 1 small molecule completed

    1 trial

  14. Divalproex Sodium Extended-release 250mg

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 1 small molecule active

    1 trial

  15. Hydrocodone Bitartrate extended-release tablet

    Teva Pharma GmbH

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  16. Hydrocodone bitartrate extended-release tablet

    Teva Pharma GmbH

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  17. Lamotrigine Extended Release

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  18. Nifedipine 60 MG Extended Release Oral Tablet

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  19. Olanzapine Extended Release

    Teva Pharma GmbH

    Schizophrenia, Schizoaffective Disorder

    phase 1 small molecule completed

    1 trial

  20. Semaglutide Extended-release for Injectable Suspension, 1 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes Mellitus, Type 2

    phase 1 small molecule active

    1 trial

  21. Sialic Acid Extended Release (SA-ER) Tablets

    Ultragenyx UK Limited

    Hereditary Inclusion Body Myopathy (HIBM)

    phase 1 small molecule completed

    1 trial

  22. Triamcinolone Acetonide Extended-Release Injectable Suspension

    Pacira Ireland Limited

    Osteoarthritis, Knee

    phase 1 small molecule completed

    1 trial

  23. a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).

    Teva Pharma GmbH

    Pain

    phase 1 small molecule completed

    1 trial

  24. Buprenorphine Extended-Release Injection

    Indivior Pty Ltd

    Opioid Use Disorder

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources